TED.L Regulatory News (TED)

22 Mar 2005 11:00

22nd March 2005 Tepnel Life Sciences PLC (`Tepnel' or `the Company') Preliminary results reporting date Manchester, U.K. The Company (AIM: TED) announced today that it will reportits preliminary financial results for the year ended December 31st 2004 on orbefore March 31st 2005. The reporting date was previously given as March 22nd2005 and this has now been rescheduled. At an investor meeting in London today, Tepnel will be revealing headlinefigures showing a growth in sales from ‚£3.9m (year ending December 31st 2003)to ‚£10.2m (year ending December 31st 2004) including increased sales fromexisting operations of ‚£4.05m (4.5% growth from 2003) and sales fromacquisitions of ‚£6.15m. The operating loss for the year ended 31 December 2004will be in line with market expectations. At 31st December 2004, group cashbalances were ‚£2.5m.For Further Information:Tepnel Life Sciences plcBen Matzilevich, CEOGron Ffoulkes-Davies, Finance Director0161 946 2200Seymour PierceMark Percy, Corporate Finance0207 107 8000De Facto CommunicationsRichard Anderson020 7940 1000Notes to EditorsAbout Tepnel Life Sciences plcTepnel is a UK-based international life sciences company focused on moleculardiagnostics and research products and services including DNA purification kitsand reagents, scientific services for nucleic acid purification, drug analysis,genotyping and genetically modified foods. Tepnel was founded in 1992 toexploit DNA technology generated at UMIST (University of Manchester Instituteof Science and Technology) and is quoted on the AIM segment of the London StockExchange (AIM: TED). More information on Tepnel can be found at www.tepnel.com.ENDTEPNEL LIFE SCIENCES PLC